These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 35467938)
1. Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia. Brøsen JMB; Agesen RM; Alibegovic AC; Ullits Andersen H; Beck-Nielsen H; Gustenhoff P; Krarup Hansen T; Hedetoft CGR; Jensen TJ; Stolberg CR; Bogh Juhl C; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U Diabetes Technol Ther; 2022 Sep; 24(9):643-654. PubMed ID: 35467938 [No Abstract] [Full Text] [Related]
2. Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial. Pedersen-Bjergaard U; Agesen RM; Brøsen JMB; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen TJ; Juhl CB; Jensen AK; Lerche SS; Nørgaard K; Parving HH; Sørensen AL; Tarnow L; Thorsteinsson B Diabetes Obes Metab; 2022 Feb; 24(2):257-267. PubMed ID: 34643020 [TBL] [Abstract][Full Text] [Related]
3. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ; JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316 [TBL] [Abstract][Full Text] [Related]
4. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967 [TBL] [Abstract][Full Text] [Related]
5. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317 [TBL] [Abstract][Full Text] [Related]
6. Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia. Brøsen JMB; Agesen RM; Kristensen PL; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Stolberg CR; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U Diabetes Obes Metab; 2023 Jun; 25(6):1557-1565. PubMed ID: 36749303 [TBL] [Abstract][Full Text] [Related]
7. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design. Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range. Elhabashy SA; Sakr EM; Salah NY Eur J Pediatr; 2023 Apr; 182(4):1857-1868. PubMed ID: 36800034 [TBL] [Abstract][Full Text] [Related]
9. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR; Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Dong ZY; Feng JH; Zhang JF Clin Ther; 2022 Nov; 44(11):1520-1533. PubMed ID: 36763996 [TBL] [Abstract][Full Text] [Related]
11. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Zhang XW; Zhang XL; Xu B; Kang LN Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761 [TBL] [Abstract][Full Text] [Related]
12. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501 [TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727 [TBL] [Abstract][Full Text] [Related]
14. Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial. Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Jensen T; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U Diabetes Technol Ther; 2018 Mar; 20(3):247-256. PubMed ID: 29565719 [TBL] [Abstract][Full Text] [Related]
15. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus. Hemmingsen B; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147 [TBL] [Abstract][Full Text] [Related]
16. Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison. Martin ; Zhou Y; Takagi T; Tian YS Int J Clin Pharm; 2022 Jun; 44(3):587-598. PubMed ID: 35476308 [TBL] [Abstract][Full Text] [Related]
17. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250 [TBL] [Abstract][Full Text] [Related]
18. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2. Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886 [TBL] [Abstract][Full Text] [Related]
19. Assessment of the Effect of Timing of Insulin Glargine Administration (Bedtime versus Morning) on Glycemic Control in Children with Type 1 Diabetes in Cairo, Egypt: A Single Centre Experience. Shamma RA; Anwar GM; Musa N; Mira MF; Abdou M Curr Diabetes Rev; 2023; 19(4):e110422203403. PubMed ID: 35410614 [TBL] [Abstract][Full Text] [Related]
20. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O; N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]